Table 3 Sensitivity analyses around indirect effectiveness of PCV13 and co-infection assumptions in normal and pandemic influenza seasons
Normal season | ||||
|---|---|---|---|---|
Base-Case | IPD indirect effects only | No indirect effects | Halve % with bacterial co-infection | |
Cases avoided | ||||
IPD | 13,400 | 13,400 | 2,100 | 13,400 |
Hospitalized pneumonia | 57,400 | 5,000 | 5,000 | 57,400 |
Non-Hospitalized pneumonia | 341,200 | 62,300 | 62,400 | 341,200 |
Deaths averted | 2,900 | 1,200 | 40 | 2,900 |
Cost /(savings) | $ (472) M | $ 82 M | $ 299 M | ($ 472 M) |
QALYs gained | 41,524 | 18,953 | 4,484 | 41,524 |
Cost per QALY gained | dominant | $4,300 | $66,800 | dominant |
Pandemic similar to 2009–2010 H1N1 | ||||
Base-Case | IPD indirect effects only | No indirect effects | Halve % with bacterial co-infection | |
Cases avoided | ||||
IPD | 22,800 | 22,800 | 5,700 | 16,900 |
Hospitalized pneumonia | 97,700 | 13,700 | 13,900 | 72,600 |
Non-Hospitalized pneumonia | 773,800 | 170,800 | 171,900 | 504,000 |
Deaths averted | 3,700 | 1,600 | 110 | 3,200 |
Cost/(savings) | ($ 1.02 B) | ($ 130 M) | $ 180 M | ($ 676 M) |
QALYs gained | 51,637 | 25,671 | 4,844 | 44,023 |
Cost per QALY gained | dominant | dominant | $37,100 | dominant |